

10580 COMPETITIVE PROBLEMS IN THE DRUG INDUSTRY

	<u>Page</u>
5 OVERLAPPING QUALITY ASSURANCE ACTIVITIES AND OBSTACLES TO ELIMINATING THEM	30
Differences in approving firms to supply drugs and in inspecting products	30
Obstacles to eliminating overlapping quality assurance activities	32
Conclusions	33
Recommendation	33
Agency comments	34
6 SCOPE OF REVIEW	35
APPENDIX	
I Comparison of highest price paid under definite-quantity contract by VA or DPSC with the FSS price for drugs, March 1968 to December 1969	37
II Letter dated August 14, 1973, from the Assistant Secretary of Defense (Health and Environment), DOD	40
III Letter dated September 18, 1973, from the Assistant Secretary, Comptroller, HEW	45
IV Letter dated July 25, 1973, from the Deputy Administrator, VA	46
V Letter dated July 6, 1973, from the Adminis- trator, GSA	49
VI Letter dated July 20, 1973, from Assistant Director, Management and Organization, OMB	51
VII Principal VA and DOD officials responsible for the major portion of the direct pur- chases of pharmaceuticals for the Govern- ment	54